Related Experiment Video
Updated: May 3, 2026
05:55
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
Published on: December 21, 2019
6.1K
Lead optimization of HMBA to develop potent HEXIM1 inducers
Bo Zhong1, Rati Lama1, Wannarasmi Ketchart2
1Department of Chemistry, College of Sciences and Health Professions, Cleveland State University, 2121 Euclid Ave., Cleveland, OH 44115, USA.
Bioorganic & Medicinal Chemistry Letters
|February 8, 2014
Summary
New Hexamethylene bis-acetamide (HMBA) derivatives show enhanced potency in prostate cancer cells. Unsymmetrical structures improve activity and half-life, aiding clinical applications.
Area of Science:
- Medicinal Chemistry
- Cancer Biology
- Pharmacology
Background:
- Hexamethylene bis-acetamide (HMBA) is investigated for its effects on Hexamethylene bis-acetamide inducible protein 1 (HEXIM1).
- The clinical application of HMBA is limited by its short half-life.
Purpose of the Study:
- To evaluate the potency of novel HMBA derivatives in inducing HEXIM1.
- To explore structure-activity relationships for improved HMBA analogs.
- To address limitations of HMBA's short half-life for potential therapeutic use.
Main Methods:
- Testing of a series of Hexamethylene bis-acetamide (HMBA) derivatives.
- Assay of Hexamethylene bis-acetamide inducible protein 1 (HEXIM1) induction.
- Evaluation in LNCaP prostate cancer cells.
Main Results:
- Several HMBA derivatives with unsymmetrical structures demonstrated significantly enhanced activity.
- These novel analogs exhibit increased hydrophobicity compared to HMBA.
- The improved properties suggest a potential to overcome HMBA's short half-life limitation.
Conclusions:
- Unsymmetrical HMBA derivatives represent a promising class of compounds for HEXIM1 induction.
- The enhanced hydrophobicity and activity of these analogs offer a basis for further drug development.
- These findings pave the way for lead optimization using combinatorial chemistry strategies in prostate cancer research.
